A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased the company’s American Depositary Shares between June 5, 2023, and December 26, 2025. The complaint alleges that Mereo and certain executives made materially false and misleading statements regarding the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta. According to the lawsuit, the company repeatedly expressed confidence that its ORBIT and COSMIC trials would achieve statistical significance in reducing annualized fracture rates and position setrusumab for regulatory success, while concealing adverse facts about the studies’ progress. On December 29, 2025, Mereo disclosed that neither trial achieved its primary endpoint, leading to a sharp decline in its share price by over 87 percent. Investors have until April 6, 2026, to seek appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602131113PRIMZONEFULLFEED9654592) on February 13, 2026, and is solely responsible for the information contained therein.